2014

Nuvo Research Announces Director Election Results of its Annual General Meeting

MISSISSAUGA, ON, June 18, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain announced today that, at its 2013 annual and special meeting of shareholders held in Mississauga, all nominees listed in the management proxy circular dated May 1, 2013 were elected, by a show of hands, as directors of the Company.

The detailed results of the votes by proxy are as follows:

Director Nominees NUMBER OF SHARES  PERCENTAGE OF VOTES CAST 
FOR WITHHELD FOR WITHHELD
Daniel Chicoine  150,828,000   13,487,086  91.79% 8.21%
David A. Copeland 151,115,028 13,200,058 91.97% 8.03%
Anthony E. Dobranowski 150,783,278 13,531,808 91.76% 8,24%
Dr. Henrich R.K. Guntermann   151,651,492 12,663,594 92.29% 7.71%
Dr. Klaus von Lindeiner 152,817,020 11,498,066 93.00% 7.00%
John C. London 150,455,593 13,859,493 91.57% 8.43%
Dr. Jacques Messier 151,599,328 12,715,758 92.26% 7.74%
Dr. Theodore H. Stanley 153,724,344 10,590,742 93.55% 6.45%

About Nuvo Research Inc.
Nuvo is a publicly traded, Canadian specialty pharmaceutical company, headquartered in Mississauga, Ontario.  The Company is building a portfolio of products for the treatment of pain through internal research and development.  The Company's product portfolio includes Pennsaid®, Pliaglis and Synera®.  Pennsaid, a topical nonsteroidal anti-inflammatory drug (NSAID), is used to treat the signs and symptoms of osteoarthritis of the knee(s).  Pennsaid is sold in the United States by Mallinckrodt Inc., in Canada by Paladin Labs Inc. and in several European countries. Pliaglis is a topical local anesthetic cream which provides topical local analgesia for superficial dermatological procedures.  The Company has licensed worldwide marketing rights to Pliaglis to Galderma Pharma S.A., a global pharmaceutical company specialized in dermatology. Galderma launched the marketing and sale of Pliaglis in the U.S. in March of 2013 and in the E.U. in April of 2013.  Synera is a topical patch that combines lidocaine, tetracaine and heat, approved in the United States to provide local dermal analgesia for superficial venous access and superficial dermatological procedures and in Europe, for surface anaesthesia of normal intact skin.  Nuvo currently markets Synera in the United States and its licensing partner, Eurocept International B.V., has initiated a pan-European launch of Synera (under the name Rapydan) in several European countries.  The Company is also developing WF10, for the treatment of immune related diseases.  

SOURCE Nuvo Research Inc.



More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.